North Andover, MA, USA August 3, 2016 – Bach Pharma Inc., a Delaware Corporation, announced the appointment of Dr. Pravin Chaturvedi to the Board of Directors. Dr. Chaturvedi has deep experience in building biotechnology companies both as a scientist and entrepreneur. He is the President and Chief Executive Officer of Boston and Vancouver-based Pivot Pharmaceuticals, Inc., which recently acquired Boston-based IndUS Pharmaceuticals, a company concerned with the discovery and development of small molecule drugs for the treatment of cancer, diabetes and infectious diseases. IndUS was founded and led by Dr. Chaturvedi until its acquisition. Additionally, Dr. Chaturvedi is the co-founder of Florida-based Oceanyx Pharmaceuticals. He remains an advisor to San Francisco-based Napo Pharmaceuticals, where he was the President and Chief Scientific Officer. Prior to his tenures at Pivot, IndUS, and Napo, he was the President and Chief Executive Officer of Boston-based Scion Pharmaceuticals, which was acquired by Wyeth (now Pfizer). He has also served as Head of Lead Evaluation at Vertex Pharmaceuticals. Dr. Chaturvedi will support Bach’s initiatives as a key scientific advisor in addition to being a non-executive board member.
“I believe Bach has the potential for the development of treatments for neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS) which represents a very high unmet medical need and could benefit from the development of Bach’s lead candidate GVT” stated Dr. Chaturvedi about his appointment to the Board of Directors. “Dr. Chaturvedi brings extensive scientific expertise to our board and his contributions will be a key element of Bach’s future success” states Bach Pharma CEO Kelly Blackburn.
“His knowledge and experience in building successful companies will be invaluable as we move forward with the development of GVT.”
ABOUT BACH PHARMA
Bach Pharma, Inc., (BACH), a privately held pharmaceutical company, is a global leader in the development of revolutionary phthalazinedione-based therapeutics to treat life threatening diseases. BACH is targeting the development of therapies for life threatening oxidative stress-related diseases with the goal to dramatically improve patients’ lives and reduce the cost of global health care. The company’s lead candidate GVT is a novel cytoprotective agent that has powerful anti-oxidant and anti-inflammatory properties and scavenges free radicals. Research has shown that GVT can reverse oxidative stress, restore intracellular redox homeostasis and quell inflammation. GVT has the potential to treat various serious diseases of the central nervous and immune systems. Bach has intellectual property for GVT as well as multiple derivatives. The leading program will be focused on severe rare neurological diseases. Bach is a proud member of the MassBio Council and a host company for the Massachusetts Life Science Center Internship Challenge. Media Contact: Mark Henry, CFO Telephone: 978-794-5510 Email: email@example.com